Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy

IntroductionIn 2018, durvalumab was approved by the U.S. Food and Drug Administration as consolidation immunotherapy for patients with stage III NSCLC after definitive chemoradiotherapy (CRT). However, whether benefits EGFR-mutated remains unknown.MethodsWe conducted a multi-institutional retrospective analysis of unresectable who completed concurrent CRT. Kaplan-Meier analyses evaluated progression-free survival (PFS) between CRT or without durvalumab.ResultsAmong 37 patients, 13 initiated median 20 days completion. Two 12 months treatment, five discontinuing owing to progression immune-related adverse events (irAEs). Of 24 durvalumab, 16 alone eight induction EGFR tyrosine kinase inhibitors (TKIs). Median PFS 10.3 in received versus 6.9 (log-rank p = 0.993). TKI associated significantly longer (26.1 mo) compared 0.023). Six treated TKIs recurrence, one developing grade 4 pneumonitis on osimertinib.ConclusionsIn this study, did not benefit experienced high frequency irAEs. Patients initiate osimertinib may be susceptible incident Consolidation should approached caution setting further investigated treatment.